You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

VERTEPORFIN - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for verteporfin and what is the scope of patent protection?

Verteporfin is the generic ingredient in one branded drug marketed by Bausch Lomb Ireland and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for verteporfin. Two suppliers are listed for this compound.

Recent Clinical Trials for VERTEPORFIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wake Forest University Health SciencesPhase 4
Tan Tock Seng HospitalN/A
National University Hospital, SingaporeN/A

See all VERTEPORFIN clinical trials

Pharmacology for VERTEPORFIN
Drug ClassPhotoenhancer
Mechanism of ActionPhotoabsorption
Physiological EffectPhotosensitizing Activity
Anatomical Therapeutic Chemical (ATC) Classes for VERTEPORFIN

US Patents and Regulatory Information for VERTEPORFIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch Lomb Ireland VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VERTEPORFIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch Lomb Ireland VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 ⤷  Sign Up ⤷  Sign Up
Bausch Lomb Ireland VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 ⤷  Sign Up ⤷  Sign Up
Bausch Lomb Ireland VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 ⤷  Sign Up ⤷  Sign Up
Bausch Lomb Ireland VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for VERTEPORFIN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
CHEPLAPHARM Arzneimittel GmbH Visudyne verteporfin EMEA/H/C/000305
Visudyne is indicated for the treatment of:adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or;adults with subfoveal choroidal neovascularisation secondary to pathological myopia.
Authorised no no no 2000-07-27
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.